Document is current
Any future updates will be listed below
-
Authors
Petrakis, Ismene https://orcid.org/0000-0002-6894-5946
Springer, Sandra A.
Davis, Cynthia
Ralevski, Elizabeth
Gu, Lucy
Lew, Robert
Hermos, John
Nuite, Melynn
Gordon, Adam J.
Kosten, Thomas R.
Nunes, Edward V.
Rosenheck, Robert
Saxon, Andrew J.
Swift, Robert
Goldberg, Alexa
Ringer, Robert
Ferguson, Ryan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04375033 at ClinicalTrials.govDocuments that mention this clinical trial
Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans
https://doi.org/10.1186/s13722-022-00286-6
-
Funding
Funding for this research was provided by:
U.S. Department of Veterans Affairs (Cooperative Studies Program)
- License Information
-
More Information
Article History
Received: 27 April 2021
Accepted: 10 January 2022
First Online: 31 January 2022
Declarations
:
: This study is approved by the VA-Central Institutional Review Board (CIRB).
: Not applicable.
: Authors S. Springer and I. Petrakis have received consultation honoraria and have received study drug donated in-kind from Alkermes Inc; Author S. Springer has received study drug donated in-kind from Indivior Inc. for a NIDA-funded study. TR Kosten has received consultation honoraria from Alkermes Inc. Author A. Saxon received consultation honorarium from Indivior, Inc., received consultation honorarium and travel support from Alkermes, Inc., and royalties from UpToDate, Inc. Author Adam J. Gordon receive royalties from UpToDate, Inc., for an online chapter unrelated to this manuscript.
